Diflunisal

Diflunisal
Clinical data
Trade namesDolobid
AHFS/Drugs.comMonograph
MedlinePlusa684037
Pregnancy
category
  • AU: C
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNING[1]Rx-only
Pharmacokinetic data
Bioavailability80-90%
Protein binding>99%
MetabolismHepatic
Elimination half-life8 to 12 hours
ExcretionRenal
Identifiers
  • 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.040.925 Edit this at Wikidata
Chemical and physical data
FormulaC13H8F2O3
Molar mass250.201 g·mol−1
3D model (JSmol)
  • O=C(O)c1cc(ccc1O)c2ccc(F)cc2F
  • InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18) checkY
  • Key:HUPFGZXOMWLGNK-UHFFFAOYSA-N checkY
  (verify)

Diflunisal is a salicylic acid derivative with analgesic and anti-inflammatory activity.[2] It was developed by Merck Sharp & Dohme in 1971, as MK647, after showing promise in a research project studying more potent chemical analogs of aspirin.[3] It was first sold under the brand name Dolobid, marketed by Merck & Co., but generic versions are now widely available. It is classed as a nonsteroidal anti-inflammatory drug (NSAID) and is available in 250 mg and 500 mg tablets.

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Boullard O, Leblanc H, Besson B (2012). "Salicylic Acid". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a23_477. ISBN 3527306730.
  3. ^ Adams SS (1999). "Ibuprofen, the propionics and NSAIDs: personal reflections over four decades". Inflammopharmacology. 7 (3): 191–7. doi:10.1007/s10787-999-0002-3. PMID 17638090. S2CID 11074565.